RECRUITING

Cancer Survivor Cardiomyopathy Detection

Description

The purpose of this study is to improve the cardiovascular care of adult cancer survivors. The goal is to obtain the data necessary to plan and develop a nation-wide network of a screening program that can help provide cost-effective and long-term monitoring.

Conditions

Cardiovascular DiseasesCancer
Talk to us

Related Conditions:

Cardiovascular DiseasesCancer

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to improve the cardiovascular care of adult cancer survivors. The goal is to obtain the data necessary to plan and develop a nation-wide network of a screening program that can help provide cost-effective and long-term monitoring.

CAncer Survivor CArdiomyopathy DEtection Pilot Study

Cancer Survivor Cardiomyopathy Detection

Condition
Cardiovascular Diseases
Intervention / Treatment

-

Contacts and Locations

Rochester

Mayo Clinic in Rochester, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * ≥18 years of age prior to enrollment and anthracycline start date
  • * diagnosis of breast cancer, lymphoma, or sarcoma with either planned or at 1 year after completion of anthracycline therapy, including patients from 6-12 months and greater than 1 year post-anthracycline exposure.
  • * LVEF \<50% or prior confirmed history of cardiomyopathy, heart failure, persistent atrial fibrillation, left bundle branch block, or paced rhythm
  • * Individuals with pacemakers, defibrillators, or other implanted electronic devices
  • * Inability/unwillingness of individual to give written informed consent

Ages Eligible for Study

18 Years to 99 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mayo Clinic,

Joerg Herrmann, MD, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

2024-10-31